BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

(1) Background: BET bromodomain proteins regulate transcription by binding acetylated histones and attracting key factors for, e.g., transcriptional elongation. BET inhibitors have been developed to block pathogenic processes such as cancer and inflammation. Despite having potent biological activiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Funck-Brentano, Elisa, Vizlin-Hodzic, Dzeneta, Nilsson, Jonas A., Nilsson, Lisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889204/
https://www.ncbi.nlm.nih.gov/pubmed/32603264
http://dx.doi.org/10.1080/15592294.2020.1786319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889204/
https://www.ncbi.nlm.nih.gov/pubmed/32603264
http://dx.doi.org/10.1080/15592294.2020.1786319

Ejemplares similares